Skip to Main Content

Advertisement

Skip Nav Destination

OnlineFirst

Research Article December 6 2023
TAS0313 Plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Mol Cancer Ther (2023)
Models and Technologies December 6 2023
SKP2 Knockout in Rb1/p53–Deficient Mouse Models of Osteosarcoma Induces Immune Infiltration and Drives a Transcriptional Program with a Favorable Prognosis
Mol Cancer Ther (2023)
Research Article December 6 2023
Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer
Mol Cancer Ther (2023)
Targeting Drug Resistance December 5 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Mol Cancer Ther (2023)
Small Molecule Therapeutics December 5 2023
Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis
Mol Cancer Ther (2023)
Large Molecule Therapeutics December 5 2023
Design and Evaluation of Phosphonamidate-Linked Exatecan Constructs for Highly Loaded, Stable, and Efficacious Antibody–Drug Conjugates
Mol Cancer Ther (2023)
Review December 5 2023
Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy
Mol Cancer Ther (2023)
Models and Technologies December 5 2023
Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models
Mol Cancer Ther (2023)
Subject Review December 5 2023
Roles of cGAS-STING pathway in radiotherapy combined with immunotherapy for hepatocellular carcinoma
Mol Cancer Ther (2023)
Research Article November 30 2023
Darolutamide added to docetaxel augments antitumor effect in models of prostate cancer through cell cycle arrest at the G1-S transition
Mol Cancer Ther (2023)
First Disclosure November 30 2023
XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies
Mol Cancer Ther (2023)
Research Article November 30 2023
Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer
Mol Cancer Ther (2023)
Research Article November 28 2023
Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma
Mol Cancer Ther (2023)
Subject Review November 28 2023
Targeting Dysregulated Ion Channels in Liver Tumors with Venom Peptides
Mol Cancer Ther (2023)
Research Article November 23 2023
PUMA/RIP3 mediates chemotherapy response via necroptosis and local immune activation in colorectal cancer
Mol Cancer Ther (2023)
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers November 22 2023
Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
Mol Cancer Ther (2023)
Large Molecule Therapeutics November 22 2023
An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy
Mol Cancer Ther (2023)
Targeting Drug Resistance November 22 2023
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
Mol Cancer Ther (2023)
Research Article November 18 2023
Oncogenic cells of renal embryonic lineage sensitive to the small molecule inhibitor QC6352 display depletion of KDM4 levels and disruption of ribosome biogenesis
Mol Cancer Ther (2023)
Subject Review November 18 2023
Interleukin 35: New Target for Immunotherapy Targeting the Tumor Microenvironment
Mol Cancer Ther (2023)
Small Molecule Therapeutics November 17 2023
Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma
Mol Cancer Ther (2023)
First Disclosure November 16 2023
CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
Mol Cancer Ther (2023)
Large Molecule Therapeutics November 16 2023
Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
Mol Cancer Ther (2023)
First Disclosure November 15 2023
A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Mol Cancer Ther (2023)
Research Article November 15 2023
The antipsychotic drug penfluridol inhibits N-linked glycoprotein processing and enhances T-cell-mediated tumor immunity
Mol Cancer Ther (2023)
Research Article November 11 2023
Radiation Synergizes with IL-2/IL-15 Stimulation to Enhance Innate Immune Activation and Antitumor Immunity
Mol Cancer Ther (2023)
Large Molecule Therapeutics November 9 2023
Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Mol Cancer Ther (2023)
Small Molecule Therapeutics November 9 2023
Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling
Mol Cancer Ther (2023)
Large Molecule Therapeutics November 9 2023
Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer
Mol Cancer Ther (2023)
Research Article November 8 2023
Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models
Mol Cancer Ther (2023)
Research Article November 3 2023
Genetic silencing of AKT induces melanoma cell death via mTOR suppression
Mol Cancer Ther (2023)
Research Article November 1 2023
Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
Mol Cancer Ther (2023)
Targeting Drug Resistance November 1 2023
MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling
Mol Cancer Ther (2023)
Small Molecule Therapeutics November 1 2023
Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence
Mol Cancer Ther (2023)
Research Article October 31 2023
TAS0612, a novel RSK, AKT, and S6K inhibitor, exhibits antitumor effects in preclinical tumor models
Mol Cancer Ther (2023)
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers October 31 2023
SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
Mol Cancer Ther (2023)
Subject Review October 30 2023
Adoptive T cells therapy in solid tumors: state-of-the art, current challenges, and upcoming improvements
Mol Cancer Ther (2023)
Research Article October 11 2023
Bifunctional inhibitor reveals NEK2 as a therapeutic target and regulator of oncogenic pathways in lymphoma
Mol Cancer Ther (2023)
Close Modal

or Create an Account

Close Modal
Close Modal